Ultra-high molecular weight polyethylene is a semicrystalline polymer, which means that a portion of the molecules is in a solid crystalline phase and the remaining portion is in a rubbery amorphous phase. Varying the polymer chemistry in the two phases can alter the mechanical properties of the material. When highly cross-linked polyethylene is formed, the cross-links occur in the amorphous but not the crystalline region. Remelting after irradiation-induced cross-linking neutralizes the free radicals that are caused by irradiation but also decreases the amount of crystallinity. Decreased crystallinity can contribute to a decrease in mechanical properties. Annealing below the melt temperature after irradiation retains a higher level of crystallinity. However, heating below the melt temperature does not neutralize irradiation-induced free radicals that can then react with oxygen, causing oxidative degradation. Newer "second-generation" highly cross-linked polyethylenes have been developed that are annealed below the melt temperature, but use either a pharmacologic antioxidant, mechanical deformation, or sequential low-dose irradiation and annealing treatments rather than heating above the melt point to neutralize residual free radicals. High-pressure treatment at elevated temperatures also can increase crystallinity. However, increased crystallinity is associated with an increase in modulus and contact stress, which can increase wear. Although cross-linking ultra-high molecular weight polyethylene can reduce wear, currently available highly cross-linked polyethylenes also decrease mechanical properties when compared with conventional ultra-high molecular weight polyethylene, so that use of these materials in total knee arthroplasty may contribute to mechanical failure of the bearing surface.

Polls results

On a scale of 1 to 10, rate how much this article will change your clinical practice?

NO change
BIG change
83% Article relates to my practice (10/12)
16% Article does not relate to my practice (2/12)
0% Undecided (0/12)

Will this article lead to more cost-effective healthcare?

83% Yes (10/12)
8% No (1/12)
8% Undecided (1/12)

Was this article biased? (commercial or personal)

0% Yes (0/12)
91% No (11/12)
8% Undecided (1/12)

What level of evidence do you think this article is?

8% Level 1 (1/12)
8% Level 2 (1/12)
41% Level 3 (5/12)
25% Level 4 (3/12)
16% Level 5 (2/12)